Laboratoires Pierre Fabre and XtalPi announced on November 9, 2026 an agreement to discover novel small-molecule clinical candidates across multiple research programs. XtalPi will contribute integrated AI capabilities and a robotics platform, while Pierre Fabre will select and advance compounds in oncology, potentially dermatology, and rare diseases. The partners are directing that work toward challenging and historically hard-to-drug targets, which they associate with significant unmet medical…